Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 1 mg/ml - solution - excipient ingredients: benzoic acid; purified water; hydrochloric acid - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; hydrochloric acid; benzoic acid; purified water - risperidone bnm is indicated for the treatment of schizophrenia and related psychoses.,risperidone bnm is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,risperidone bnm is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,risperidone bnm is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,risperidone bnm is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide red - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; benzoic acid; purified water; hydrochloric acid - rixadone is indicated for the treatment of schizophrenia and related psychoses.,rixadone is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,rixadone is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,rixadone is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,rixadone is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.